BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:511-20. [PMID: 34344612 DOI: 10.1016/j.hbpd.2021.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Li W, Wu R, Zhang S, Zhao Y, Li L, Hu Z, Su Q, Mang Y, Zhang X, Dong Y, Zheng K, Ran J, Li L. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma. Clin Transl Oncol 2023. [PMID: 36708372 DOI: 10.1007/s12094-023-03084-x] [Reference Citation Analysis]
2 Tan K, Wang K, Zhao A, Liu Z, Song W, Cheng Q, Li X, Chen Z, Yuan Y, Yang Z. Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene. Med Oncol 2022;40:14. [PMID: 36352167 DOI: 10.1007/s12032-022-01875-w] [Reference Citation Analysis]
3 Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 2022;13:1070961. [PMID: 36601120 DOI: 10.3389/fimmu.2022.1070961] [Reference Citation Analysis]
4 Chu Y, Liu H, Chen Y, Chou C, Yeh C. WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996820] [Reference Citation Analysis]
5 Liu P, Wang X, Liu H, Wang S, Xu Q, Wang L, Xu X, Cai J. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.11.010] [Reference Citation Analysis]
6 Xue C, Gu X, Zhao Y, Jia J, Zheng Q, Su Y, Bao Z, Lu J, Li L. Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes. Cancer Cell Int 2022;22:308. [PMID: 36217206 DOI: 10.1186/s12935-022-02730-8] [Reference Citation Analysis]
7 Yuan ZG, Zeng TM, Tao CJ. Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary Pancreat Dis Int 2022;21:440-9. [PMID: 36115807 DOI: 10.1016/j.hbpd.2022.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
9 Xiang Z, Li J, Lu D, Wei X, Xu X. Advances in multi-omics research on viral hepatitis. Front Microbiol 2022;13:987324. [DOI: 10.3389/fmicb.2022.987324] [Reference Citation Analysis]
10 Guan M, Wang M, Wang W, Li C, Yao L, Zhu H, Yang T. Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma. Liver Research 2022. [DOI: 10.1016/j.livres.2022.08.001] [Reference Citation Analysis]
11 Ye Z, Zheng S, Chen J, Zhang Y, Yang S, Hong Y, Yang H, Xuan Z, Zhao Q. Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients? Int Immunopharmacol 2022;108:108738. [PMID: 35395468 DOI: 10.1016/j.intimp.2022.108738] [Reference Citation Analysis]
12 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yang K, Choi C, Cho H, Ahn WG, Kim SY, Shin SW, Kim Y, Jang T, Lee N, Park HC. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics 2021;13:1811. [PMID: 34834226 DOI: 10.3390/pharmaceutics13111811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]